Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABBV AbbVie Inc
- Stocks
- Healthcare
- NYSE: ABBV
Price (delayed)
$190.07
Market cap
$335.74B
P/E Ratio
80.54
Dividend/share
$6.38
EPS
$2.36
Enterprise value
$400.45B
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate
Highlights
ABBV's gross profit is up by 20% year-on-year and by 2.9% since the previous quarter
The gross margin has grown by 13% YoY
The quick ratio has contracted by 33% YoY but it has grown by 12% from the previous quarter
The debt has declined by 6% year-on-year but it rose by 4.1% since the previous quarter
ABBV's P/E is 105% above its 5-year quarterly average of 39.3 and 12% above its last 4 quarters average of 72.1
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter
Key stats
What are the main financial stats of ABBV
Market
Valuations
Earnings
Shares outstanding
1.77B
Market cap
$335.74B
Enterprise value
$400.45B
Price to earnings (P/E)
80.54
Price to book (P/B)
236.3
Price to sales (P/S)
5.86
EV/EBIT
67.33
EV/EBITDA
28.01
EV/Sales
6.98
Revenue
$57.37B
Gross profit
$40.56B
Operating income
$10.07B
Net income
$4.2B
EBIT
$5.95B
EBITDA
$14.3B
Free cash flow
$15.39B
Per share
Balance sheet
Liquidity
EPS
$2.36
EPS diluted
$2.35
Free cash flow per share
$8.7
Book value per share
$0.8
Revenue per share
$32.45
TBVPS
$23.98
Total assets
$136.17B
Total liabilities
$134.7B
Debt
$69.89B
Equity
$1.42B
Working capital
-$8.73B
Debt to equity
49.22
Current ratio
0.76
Quick ratio
0.48
Net debt/EBITDA
4.53
Margins
Efficiency
Dividend
EBITDA margin
24.9%
Gross margin
70.7%
Net margin
7.3%
Operating margin
17.6%
Return on assets
3%
Return on equity
95.6%
Return on invested capital
9.2%
Return on capital employed
6%
Return on sales
10.4%
Dividend yield
3.36%
DPS
$6.38
Payout ratio
270.3%
ABBV stock price
How has the AbbVie stock price performed over time
Intraday
2.96%
1 week
-3.06%
1 month
8.58%
1 year
18.24%
YTD
6.96%
QTD
-9.28%
Financial performance
How have AbbVie's revenue and profit performed over time
Revenue
$57.37B
Gross profit
$40.56B
Operating income
$10.07B
Net income
$4.2B
Gross margin
70.7%
Net margin
7.3%
The net margin has declined by 34% year-on-year and by 3.9% since the previous quarter
The company's net income fell by 30% YoY
The operating margin has declined by 25% year-on-year but it rose by 9% since the previous quarter
The operating income has contracted by 21% YoY but it has grown by 10% from the previous quarter
Price vs fundamentals
How does ABBV's price correlate with its fundamentals
Growth
What is AbbVie's growth rate over time
Valuation
What is AbbVie stock price valuation
P/E
80.54
P/B
236.3
P/S
5.86
EV/EBIT
67.33
EV/EBITDA
28.01
EV/Sales
6.98
ABBV's P/E is 105% above its 5-year quarterly average of 39.3 and 12% above its last 4 quarters average of 72.1
The EPS has contracted by 30% YoY
ABBV's price to book (P/B) is 107% higher than its last 4 quarters average of 114.4
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter
ABBV's P/S is 22% above its 5-year quarterly average of 4.8 but 2.3% below its last 4 quarters average of 6.0
ABBV's revenue is up by 5% year-on-year
Efficiency
How efficient is AbbVie business performance
The ROE has soared by 73% YoY and by 35% from the previous quarter
AbbVie's ROIC has decreased by 39% YoY
The ROS has contracted by 38% YoY
AbbVie's return on assets has decreased by 30% YoY
Dividends
What is ABBV's dividend history
DPS
$6.38
Dividend yield
3.36%
Payout ratio
270.3%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did AbbVie financials performed over time
The quick ratio has contracted by 33% YoY but it has grown by 12% from the previous quarter
ABBV's current ratio is down by 19% year-on-year but it is up by 15% since the previous quarter
The company's debt to equity has surged by 144% QoQ
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.